Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

E. Goss, Paul; N. Ingle, James; Martino, Silvana; J. Robert, Nicholas; B. Muss, Hyman; Piccart, Martine; Castiglione, Monica; Tu, Dongsheng; E. Shepherd, Lois; I. Pritchard, Kathleen; B. Livingston, Robert; E. Davidson, Nancy; Norton, Larry; A. Perez, Edith; S. Abrams, Jeffrey; Cameron, David; Palmer, Michael; L. Pater, Joseph

doi:10.1093/jnci/dji250

Public

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

Published in JNCI Journal of the National Cancer Institute • Sep 6, 2005

Authors:

Paul E. Goss

James N. Ingle

Silvana Martino

Abstract

BACKGROUND: Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduces the risk of such late recurrences, w...

Subject

Letrozole

Medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!